Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 11 -20 of 306 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/4/2007


11.		Phase III Randomized Study of Sequential Treatment with 3 Noncross-Resistant Chemotherapy Combinations or Standard Chemotherapy for Poor-Prognosis Intermediate Grade and Immunoblastic non-Hodgkin's Lymphoma: IDA/CDDP/ARA-C/MePRDL, IDA/VCR/BLEO/CTX/MePRDL, and IFF/DHAD/VP-16 vs Standard CHOP (Summary Last Modified 09/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				over 15				NCI				MDA-DM-94017 NCI-T94-0040D, NCT00002565, T94-0040

Last Modified: 5/8/2007 First Published: 8/1/1994


12.		Phase III Randomized Study of CHOP (CTX/DOX/VCR/PRDL) vs MCOP (DHAD/CTX/VCR/PRDL) in Patients Aged 65 Years and Over with Intermediate- or High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				65 and over								CRC-TU-NH3003 EU-93028, NCT00002576

Last Modified: 1/15/2007


13.		Phase III Randomized Study of ARA-C/DNR vs DHAD/VP-16 Induction Therapy Followed by ARA-C/DNR Consolidation Therapy in Older Patients with Previously Untreated Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				56 and over				NCI				SWOG-9333 SWOG-9333

Last Modified: 5/16/2008


14.		Phase III Study of Treatment for Childhood Acute Myeloid Leukemia: High vs Standard Dose Cytarabine in the Daunorubicin, Cytarabine, Thioguanine Induction Regimen, Multidrug Resistance (MDR) Modulation with Cyclosporine vs No MDR Modulation During Consolidation, and a Comparison of Allogeneic Bone Marrow Transplant and Consolidative Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 21				NCI				POG-9421 POG-9421

Last Modified: 2/26/2008 First Published: 6/1/1995


15.		Phase III Randomized Study of Two Induction Courses That Include Daunorubicin vs Mitoxantrone and Filgrastim (G-CSF) vs Placebo, Followed By MACE (Amsacrine, Cytarabine, and Etoposide), Then Bone Marrow Transplantation (BMT) vs MidAC (Mitoxantrone and Cytarabine) vs ICE (Idarubicin, Cytarabine, and Etoposide) Followed By BMT vs ICE Followed By MidAC in Patients With Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to physiologic 59				Other				MRC-LEUK-AML12 EU-95001, NCT00002658

Last Modified: 1/1/1998


16.		Phase II Study of Multimodality Therapy for Women with Locally Advanced Breast Cancer: Neoadjuvant Cyclophosphamide/Doxorubicin/Fluorouracil (CAF) Followed by Radiotherapy with Mitomycin Followed by Surgery Followed by Adjuvant CAF or Mitoxantrone/Fluorouracil/Leucovorin (Summary Last Modified 01/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				20 to 65				Other				YALE-HIC-7996 NCI-V95-0728

Last Modified: 12/6/2007 First Published: 1/1/1996


17.		Phase III Randomized Study of Prednisone Versus Dexamethasone Plus Cyclophosphamide, Daunorubicin, and Vincristine as Induction; Cytarabine, Mitoxantrone, Methotrexate, Leucovorin Calcium, and Asparaginase as Consolidation; Autologous Bone Marrow Transplantation; and Low- or High-Intensity Maintenance Chemotherapy With Cranial Irradiation in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 60				Other				EORTC-06951 FRE-LALA-94, NCT00002700

Last Modified: 11/29/2006 First Published: 1/1/1996


18.		Phase III Randomized Study of Induction Using Tretinoin (ATRA) and Idarubicin (IDA), 3 Sequential Consolidation Regimens Using Cytarabine Plus IDA, Followed by Mitoxantrone Plus Etoposide, and then IDA, Cytarabine, and Thioguanine, and Maintenance Using Mercaptopurine (MP) Plus Methotrexate (MTX) Versus ATRA Only Versus MP Plus MTX Alternating With ATRA Versus Observation Only With or Without Bone Marrow Transplantation in Patients With Acute Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 74								EORTC-06952 ITA-GIMEMA-AIEOP-1, NCT00002701

Last Modified: 5/8/2007 First Published: 3/1/1996


19.		Phase III Randomized Study of Acute Myeloid Leukemia in Elderly Patients (AML-13): MICE (DHAD/ARA-C/VP-16) with vs without G-CSF Followed by Oral vs Intravenous Mini-ICE (IDA/ARA-C/VP-16) Followed in Selected Patients by BAVC (BCNU/AMSA/VP-16/ARA-C) with PBSC Support

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				61 to 80								EORTC-06954 ITA-GIMEMA-AML13, NCT00002719

Last Modified: 8/10/2006


20.		Phase III Randomized Study of Induction With the ALL-2 Regimen (Cytarabine and High-Dose Mitoxantrone Based) Versus the L-20 Regimen (Vincristine and Prednisone Based) in Adults With Acute Lymphoblastic Malignancy: The ALL-4 Protocol

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				MSKCC-96015A1 NCI-V96-0881, NCT00002766

Select All on One Page


					< Previous 1 2 3 4 5 Next >

| | | | | | | |

A Service of the National Cancer Institute